Compare VERU & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | STKS |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 52.7M |
| IPO Year | 1996 | 2011 |
| Metric | VERU | STKS |
|---|---|---|
| Price | $2.74 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $22.50 | $4.70 |
| AVG Volume (30 Days) | ★ 244.5K | 20.4K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $805,722,000.00 |
| Revenue This Year | N/A | $7.47 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.66 |
| 52 Week Low | $2.05 | $1.63 |
| 52 Week High | $7.33 | $3.38 |
| Indicator | VERU | STKS |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 40.92 |
| Support Level | $2.12 | $1.66 |
| Resistance Level | $2.87 | $2.12 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 75.89 | 17.47 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.